Myocardial Fibrosis in ES-HCM
Conversely, detailed and systematic histological evaluations of quantitative and qualitative characteristics of MF in HCM-not limited to single biopsy or to samples of the anterior-basal septum obtained at surgical myectomy-are lacking. Furthermore, correlation studies between histology and CMR are few and limited to qualitative correlations, whereas quantitative correlation between the 2 methods is unresolved. Important gaps remain in our knowledge of how MF develops and whether specific patterns may suggest adverse clinical remodeling, with implications ranging from early identification of patients at risk of ES progression to the prevention of sudden cardiac death.
Based on the availability of a relatively high number of explanted hearts from ES-HCM patients, our study was designed to evaluate the overall amount of ventricular MF in the hearts to quantitatively assess its base-to-apex, endocardium-epicardium and circumferential distribution, and the histological type of MF. In a subgroup of patients, with available CMR studies, we quantitatively compared histological and in vivo findings.
Methods

Study Design
We performed a retrospective observational study of patients who underwent heart transplantation for ES-HCM at our tertiary center (S.Orsola-Malpighi University Hospital of Bologna, Italy), in the period June 1999 to March 2015. Clinical, instrumental, and laboratory data were also systematically collected. Transplantation was done for all patients because of severe heart failure symptoms unresponsive to maximal pharmacological therapy or alternative treatments (such as, cardiac resynchronization therapy and left ventricular assist device). Written informed consent for anonymous scientific use of personal data had been obtained in each case before transplantation, and IRB approval was obtained.
Diagnostic Criteria
HCM was defined, in adults, by a wall thickness ≥15 mm in 1 or more left ventricle (LV) myocardial segments as measured by any imaging technique (echocardiography, CMR, or computed tomography) in the absence of another cardiac or systemic disease that could produce a comparable magnitude of LV hypertrophy. ES-HCM was defined by an left ventricular ejection fraction (LVEF) ≤50%, with or without LV dilatation, as measured by echocardiography or CMR. Nonsarcomeric HCM phenocopies were ruled out from the study.
All patients had undergone genetic testing for the 8 sarcomeric genes most frequently associated with HCM by conventional DNA sequencing.
Pathological Analysis of Explanted Heart
The hearts were evaluated by 2 pathologists with specific expertise in cardiovascular diseases, using standards and definitions proposed by the Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology. 14 After adequate fixation in 10% formaldehyde, the hearts were cut in transverse and parallel sections of 1.0 to 1.5 cm from the apex to a section 2 cm below than the atrioventricular groove. A total of 16 specimens were obtained from each heart (excluding atria) from the following sections ( Figure 1 ): (1) basal level (3 samples: 1 from the LV, 1 from the interventricular septum [IVS], and 1 from the right ventricle [RV]); (2) medium level (an entire midventricular section divided into 10 samples: 5 from the LV walls [anterior, anterolateral, lateral, inferolateral, and inferior], 3 from the IVS [anterior, medium, and posterior], and 2 from the RV walls [anterolateral and inferolateral]); (3) apical level (3 samples: 1 from the LV, 1 from the IVS, and 1 from the RV).
Subepicardial adipose tissue, including vessel and pericardium, was removed from each individual slide specimens to avoid fibrosis overestimation.
Each specimen was sectioned using PS6 action>Magnetic Lasso Tool according to the following template: the LV specimens were subdivided into 4 layers-subepicardial, midwall, subendocardial, and trabecular; the IVS samples into 4 layers-right trabecular, right subendocardial, midwall, and left subendocardial; and the RV samples into 2 layers-trabecular and parietal ( Figure I in the Data Supplement).
This subdivision was carried out manually due to the typically high variability of LV wall thickness in ES-HCM, which would not have permitted a proper computerized division.
Histomorphometric Quantitative Analysis
Evaluation of fibrosis extent and distribution was assessed by a histomorphometric quantitative analysis using a dedicated software. The system was carefully programmed to evaluate fibrosis, highlighted in bright blue with Mallory trichrome staining in contrast to deep red-stained myocardium ( Figure 2 ). The histomorphometric analysis system has been previously validated by our group, as previously described. 15 The extent of fibrosis is expressed as a percentage of the whole examined myocardial area, at the levels shown in Figure 1 (See also Data Supplement).
Fibrosis Type Assessment
From a qualitative point of view, we classified MF as (1) interstitialperimyocyte and (2) replacement type, according the following criteria. Interstitial-perimyocyte: fine collagen bundles-10-to 500-µm thickness-surrounding and enveloping single myocells or groups of myocells; replacement type (or scar-like): collagen scars of uninterrupted fibrosis, ranging from microscopic foci >2 mm to larger spots. Because the morphometric system previously described can only measure the overall fibrosis as it seems after Mallory staining (without any distinction of fibrosis type), we introduced a semiquantitative, visual evaluation of each type of fibrosis for all the 16 specimens:
1. Score 0 when absent 2. Score + when present in ≤30% of the examined myocardium 3. Score ++ when present in >30% but <60% of the examined myocardium 4. Score +++ when present in ≥60% of the examined myocardium Specimens with score +++ for replacement fibrosis and score 0 or 1+ for the interstitial fibrosis were defined as mainly replacement fibrosis. Specimens with score +++ for interstitial fibrosis and score 0 or 1+ for the replacement fibrosis were defined as mainly interstitial fibrosis; the others were defined as mixed fibrosis. Each patient was classified according to the number of qualifying specimens as having mainly replacement fibrosis (≥60%) or mainly interstitial fibrosis (≥60%) or mixed fibrosis (near equal number).
Microvasculature
For each specimen, the presence of arteriolar (<500 µm) abnormalities, including tunica media hypertrophy and fibrosis and intimal hyperplasia, was evaluated in a semiquantitative manner. HCM-related microvasculopathy (small vessel disease) was classified as mild if generating a lumen stenosis <30%, moderate between 30% and 60%, and severe >60%. Moreover, for each specimen, the topographical association of arteriolar abnormalities with different types and severity of fibrosis was described.
CMR Imaging and Image Analysis
CMR was performed on a 1.5-T scanner (Signa Twin Speed Excite, General Electric; Milwaukee, WI) with surface coils and prospective ECG triggering, using standard protocols. 8 Methodological details are reported in the Data Supplement. Myocardial Fibrosis in ES-HCM
Statistical Analysis
After verification of the normal distribution of the variables, continuous variables were expressed as mean value±SDs; categorical variables were expressed as numbers (%). The Stata software v.13.0 package (StataCorp; College Station, TX) was used for all analyses. For all comparisons, a P value <0.05 was considered significant. All P values are 2-sided.
Interobserver variability was assessed for the determination of the type of fibrosis, in a subgroup of 48 specimens, by 2 expert pathologists; concordance in classifying the type of fibrosis was 90%.
Data were analyzed in a double-blinded fashion, that is, analyses by the pathologist who sampled hearts and performed the sectioning (using PS6), the cardiologist who analyzed the pathological images (using IPA 7.0), and the radiologist who analyzed CMR images were performed independently.
Results
Clinical and Demographic Data
Thirty-five ES-HCM explanted hearts were available. Four cases with HCM phenocopies and 1 with previous alcohol septal ablation (1 year before heart transplantation) were excluded; the study population, therefore, consisted of 30 hearts (Table 1) . At least 1 pathogenic sarcomeric mutation was documented in 53.3% of patients ( Table I in the Data Supplement) . Fourteen patients had previously been implanted with implantable cardioverter defibrillator (in the remaining case, transplant Figure 3 shows the overall fibrosis detected in each of the 30 examined hearts; the average amount of fibrosis was 37.3±8.4%. The distribution of different types of fibrosis across the LV is shown in Figure 4 . Fibrosis was mainly replacement type in 16 patients (53.3%), mixed in 10 (33.3%), and mainly perimyocyte in 4 (13.3%). Details about the overall amount and type of fibrosis in each qualifying specimen are shown in Table II in the Data Supplement. Base-to-apex distribution of fibrosis, expressed as mean of the single specimen values, are shown in Table 2 ; the following segmental aggregations were considered: LV+IVS+RV; LV+IVS; LV only; IVS only; and RV only. There was a progressive increase in fibrosis from base to apex, which was significant for each segmental aggregation ( Table 2 ). Figure 5 shows the circumferential distribution of fibrosis at the midventricular level and the mean value of fibrosis in each segment. The LV inferior wall was the most affected (24.3%) followed by the anterolateral (15.8%) and anterior (11.9%) walls. The IVS was homogeneously involved, whereas the least involved segment was the inferolateral wall (7.0%). As expected, the RV was only marginally involved by fibrosis, (inferior wall and anterior wall were 4.5% and 3.4%, respectively). Figure 6 shows the epicardial-endocardial distribution of fibrosis. Fibrosis was more extensive in the midventricular layer (mean value 33.4%), whereas it distributed evenly between epicardium, endocardium, and trabecular layer (20.3%, 20.2%, and 26.1%, respectively).
Extent, Type, and Distribution of Fibrosis
Circumferential and Endocardial-Epicardial Distribution (Midventricular Short-Axis Section)
Prevailing Fibrosis Pattern
Based on the distribution of fibrosis across the 4 myocardial layers, 1 of the 4 prevailing patterns was attributed to each patient: (1) midwall, (2) midwall and subendocardial, (3) midwall and subepicardial, and (4) transmural. The most frequent pattern was midwall (33.3%), with an equal distribution of the remaining patterns: midwall and subepicardial 23.3%, transmural 23.3%, and midwall and subendocardial 20%. The subendocardium and subepicardium were never involved exclusively ( Table II in 
Clinical Correlates
Only mild, nonsignificant differences were observed in the 3 main subgroups of patients with the prevalence of replacement, mixed, or perimyocyte fibrosis ( Table III in the Data  Supplement) .
Patients with perimyocyte fibrosis type were all men, whereas those with mixed fibrosis were mostly women; patients with perimyocyte fibrosis were older than those with mixed fibrosis both at HCM diagnosis, at ES-HCM diagnosis and at heart transplantation time; patients with replacement fibrosis type fell between these 2 groups. Patients with mixed type fibrosis had a shorter time from diagnosis of ES-HCM to heart transplantation compared with those with type perimyocyte fibrosis. The degrees of overall fibrosis in the examined heart and of fibrosis amount in the midventricular short-axis section were more severe in patients with replacement fibrosis type.
Quantitative Comparison Between Late Gadolinium Enhancement and Histological Fibrosis
Comparison between fibrosis quantified by late gadolinium enhancement (LGE) CMR (using 6 SD) and that of histopathologically quantified (for the subgroup of 4 patients in whom CMR was available) is shown in Table 3 ( Table IV in the Data Supplement reports values for fibrosis detected in LV and IVS in midventricular short-axis section). Generally, there was a good correlation between the 2 methods ( Figure 7) . LGE underestimated fibrosis extent in patient 4, who had mainly perimyocyte fibrosis, because of the intrinsic limitations of LGE in identifying interstitial collagen deposition.
Fibrosis and Microvascular Remodeling
All segments (131/131) with severe scar-like fibrosis were associated with microvasculopathy (small vessel disease) characteristic of HCM 16 (Figure 8 ), which was severe in 86 (65.6%) and showed a multifocal/diffuse distribution in 123 (93.9%). Conversely, 20 of 25 segments with severe perimyocyte fibrosis were associated with microvasculopathy, that was severe in only 15% (3/20; P=0.04) and in a multifocal/diffuse pattern in 75% (15/20) . All segments with severe mixed fibrosis were associated with multifocal/diffuse microvasculopathy, showing severe abnormalities in 5 of 20 (25%).
Discussion
This study provides the first detailed quantitative histological evaluation of type, amount, and distribution of ventricular MF in ES-HCM and offers some insights into the pathogenesis of this poorly understood clinical evolution of HCM. In all the explanted hearts of our series, MF was extensive (Figure 3 [17] [18] [19] The only other published quantitative evaluation of MF in an entire heart is a case report of a single patient with ES-HCM who underwent transplantation for heart failure, 11 in whom collagen constituted 19% of the examined heart.
This considerable amount of fibrosis explains the severely depressed LVEF in our patients (27±6.9%). Of note, an inverse relationship between LVEF and fibrosis has been observed in vivo with CMR and holds true also for any degree of fibrous substitution of the myocardium, even when milder than that was seen in our series. 20 CMR has extensively used to evaluate fibrosis quantitatively, albeit indirectly. It is widely accepted that CMR can provide an accurate, noninvasive assessment of replacement LGE-a correlation that was confirmed by the small subgroup of patients in our study. 13, 20 In patients with LVEF <50%, Olivotto et al 20 reported a median value of LGE of 29% (interquartile range: 16%-40%). Beyond the correlation at the time of the study, the quantity of LGE predicts the probability of developing ES-HCM, even with a normal EF at the time of CMR. In the largest available study, the presence of LGE >20% of LV mass conveyed a >3-fold increase in the risk of developing ES-HCM at 5 years (compared with patients without LGE). 8 Of note, studies involving LGE are only capable of assessing replacement fibrosis, whereas interstitial collagen deposition represents an equally important aspect of HCM and may influence decisively both development of phenotype and disease course. The newly introduced T1-mapping methods, capable of assessing interstitial fibrosis, will likely add to our capability of assessing the whole burden of fibrosis in HCM hearts and our understanding of disease progression. 12, 13, [20] [21] [22] Our findings expand the knowledge about the relationship between CMR-detected fibrosis and LV function. Other studies assessed fibrosis in selected samples from hearts of non-ES patients with HCM. Shirani et al 23 evaluated transmural sections of IVS from 16 children or young adults who died suddenly and found abnormal values compared with control subjects (mean value 16.7±9.1%). Chan et al 24 considered the areas of insertion of the RV on the IVS trying to find a morphological basis for LGE presence at these sites, in 20 hearts of patients with HCM who died because of sudden cardiac death (no end-stage evolution). In this semiquantitative analysis (score 0-3), the authors report the presence of confluent scar in a single case, whereas interstitial fibrosis had a mean value of 1.5% to 1.7%. Differently, several studies are available in which MF was quantified in myectomy specimens from patients with obstructive HCM and normal LVEF, and these reported an MF percentage ranging from 7% to 23%. [25] [26] [27] With the limits of a classification that could lead to an oversimplification, our study showed at least 3 qualitative types of fibrosis, that is, prevalently replacement (or scar-like), prevalently interstitial-perimyocyte, and mixed. Replacement fibrosis was the most represented ( Figure 4 ; Table 2 ), whereas only a small percentage of patients had interstitial-perimyocyte fibrosis, and the remaining patients (one third) showed mixed fibrosis. This preponderance of scar-like fibrosis contrasts with the findings from myectomy specimens obtained from patients with an obstructive form and normal LVEF [25] [26] [27] in whom interstitial fibrosis is clearly prevalent with a ratio around 6:1. However, it has to be noted that surgical myectomies are performed in patients with a typically hypercontractile LV (a necessary prerequisite for the development of Table 3 obstruction) and are, therefore, at the opposite end of the disease spectrum compared with ES-HCM. Detailed analysis of the distribution of fibrosis along the 3 axes (longitudinal, circumferential, and transmural) is one of the qualifying aspects of our pathological study. Considering the longitudinal axis, a clear base-to-apex gradient was present with a significant increase in the amount of MF from the base toward the apex, which was severely affected by fibrosis (especially considering LV plus IVS; Table 3 ). This base-toapex gradient is a distinctive feature of sarcomeric ES-HCM, especially when compared with other cardiomyopathies with a hypertrophic phenotype-cardiac amyloidosis in particularwhere the LV apex is relatively spared (28, 29) . Strain rate evaluated by speckle-tracking echocardiography can detect this feature and provide a useful clue for differential diagnosis. 28, 29 These findings support the view of the LV apex as an Achilles heel in HCM hearts, as also suggested by the formation on apical aneurysms in selected patients, who are at increased risk of arrhythmic events and intraventricular thrombosis. Of note, only in a portion of these patients, aneurysm formation is explained by the presence of midventricular obstruction with abnormal systolic stress on the apical segments, whereas in the other the phenomenon seems to be spontaneous. 30 Circumferential fibrosis was not homogeneously distributed in all LV segments. Indeed, the maximum amount of fibrosis was identified in the inferior, anterior, and anterolateral LV walls, with the IVS consistently involved, whereas the inferolateral LV wall was generally spared ( Figure 5 ). The extent of fibrosis was severe (≥40%) in all segments of the midventricular short-axis section, except for the inferolateral LV wall and the RV walls, where it was moderate. The anterior and inferior IVS were slightly more affected than the mid-IVS, whereas the RV-IVS junction did not show distinctive histological features ( Figure 5 ). The latter finding represents a discrepancy with the common evidence of junctional LGE by CMR in nonfailing HCM patients. 24 Epicardial-endocardial distribution was one of the most interesting features of our work, showing that the midwall was the most affected layer ( Figure 6 ), whereas fibrosis was homogeneously distributed in the remaining layers. Although there was considerable heterogeneity among patients, the predominant pattern was midwall ( Table I in the Data Supplement), followed by midwall and subepicardial, by transmural and by midwall and subendocardial. It is essential to note that the subendocardium and the subepicardium may be involved, but never exclusively so. These results allow the assumption that fibrosis initially affects midwall layer and later-depending on the prevailing pathogenetic mechanism (myocardial ischemia, collagen production, and fibroblast proliferation)-extends at subepicardium sometimes at subendocardium, becoming transmural only in advanced disease stages. This feature clearly distinguishes sarcomeric ES-HCM from ischemic heart disease-where fibrosis is mainly subendocardial and spreads from subendocardium toward subepicardium-and from arrhythmogenic cardiomyopathy-where fibrosis is mainly subepicardial with a subepicardial-subendocardial progression.
. Correlation Between CMR-LGE and Histological Quantification of Myocardial Fibrosis: Overall Fibrosis
Another defining aspect of our study was the systematic analysis of MF into the RV. The RV was always involved by fibrosis, but in a variable fashion, and to a lesser extent compared with the IVS and LV. Also the RV shows a greater involvement of the apex with respect to the base. Circumferential distribution of fibrosis showed a slightly greater involvement of the RV inferior wall. Because the RV rarely shows areas of LGE in nonfailing HCM patients, a consistent and significant involvement of the RV in ES-HCM supports the view that diffuse disease leading to biventricular dysfunction is the substrate of refractory heart failure. Severe LV dysfunction alone is often well tolerated from a clinical and hemodynamic standpoint, until RV failure supervenes, often representing a veritable turning point in clinical course and leading to rapid demise. On the basis of our finding, assessment of RV fibrosis and function in vivo becomes an important aim of cardiac imaging in HCM.
Pathogenetic Hypotheses
Insights into the pathogenesis of ES-HCM and significance of MF as part of the HCM phenotype have emerged from this study. Rate and extent of fibrous substitution of the myocardium seem to be the key factor in the ES-HCM development. Replacement of more than one third of LV myocardium is associated with overt LV dysfunction. The vast majority of fibrosis is scar-like and probably is the result of ischemic mechanisms because of the anatomic, flow-limiting abnormalities of the small coronary arteries (Figure 8 ). Conversely, the role of interstitial-perimyocyte fibrosis is poorly understood, but our results provide further data to what was previously observed in other studies, 12, 13, 21 that is, at initial stages, there is a formation of interstitial fibrosis then with the progression of the disease, fibrosis converges in the areas of dense scar-indeed younger patients tend to have mixed fibrosis, whereas older patients showed only scar-like fibrosis. The midwall is the preferential layer for the development of both types of fibrosis, the fibrotic burden is maximal at the apex of the heart and the inferolateral LV wall is always relatively spared. This complex scenario takes place in young adults (younger than patients with the classic non-ES-HCM) frequently with familial HCM suggesting a clear genetic substrate (that we were not able to identify with standard genetic testing). Severe disease of small coronary vessels topographically related to large areas of replacement fibrosis seems to play a relevant role. The genesis of these microvascular abnormalities in HCM is unknown. A unifying hypothesis suggests that, during cardiac colonization, the pluripotent epicardiumderived cells differentiating into the coronary microvasculature may react to the abnormally contracting cardiomyocytes by a putative mechanism of mechanotransduction, leading to abnormal gene expression and differentiation, ultimately resulting in adverse vascular remodeling. 26 The same mechanism might also explain the interstitial fibrosis and primary mitral valve abnormalities of HCM. 31 These findings reinforce the emphasis on long-term surveillance of MF by CMR imaging in patients with HCM to timely identify patients at risk of progression and potentially interfere with the pathogenetic mechanisms using the standard heart failure therapeutic armamentarium. On the basis of the present findings, any extent of fibrosis >20% of the whole LV should be regarded as high risk for clinical deterioration, irrespective of clinical manifestations and global systolic function. Of note, this threshold is in perfect agreement with the large CMR-based study by Chan et al, 8 who identified a similar extent of LGE as a powerful predictor of heart failurerelated (and arrhythmic) events. 
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